ECSP15008695A - Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa - Google Patents
Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfaInfo
- Publication number
- ECSP15008695A ECSP15008695A ECIEPI20158695A ECPI201508695A ECSP15008695A EC SP15008695 A ECSP15008695 A EC SP15008695A EC IEPI20158695 A ECIEPI20158695 A EC IEPI20158695A EC PI201508695 A ECPI201508695 A EC PI201508695A EC SP15008695 A ECSP15008695 A EC SP15008695A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitor
- optionally
- pi3k
- egfr
- raf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
La presente invención se refiere a una combinación terapéutica, la cual comprende: (a) un inhibidor de B-Raf, (b) un inhibidor del receptor del factor de crecimiento epidérmico (EGFR) y, opcionalmente, (c) un inhibidor de PI3K, útil para su 5 administración separada, simultánea o en secuencia en un sujeto que lo necesite, para el tratamiento o la prevención de una enfermedad proliferativa. La presente invención se refiere en especial a una combinación terapéutica, la cual comprende: (a) un inhibidor de B-Raf de la fórmula: 10 o una sal farmacéuticamente aceptable del mismo (posteriormente referido en la presente como el Compuesto A), (b) un inhibidor del receptor del factor de crecimiento epidérmico (EGFR) y, opcionalmente, 15 (c) un inhibidor de PI3K.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680473P | 2012-08-07 | 2012-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP15008695A true ECSP15008695A (es) | 2019-03-29 |
Family
ID=48980368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI20158695A ECSP15008695A (es) | 2012-08-07 | 2015-03-06 | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa |
Country Status (39)
Country | Link |
---|---|
US (1) | US9474754B2 (es) |
EP (2) | EP2882440B1 (es) |
JP (3) | JP6342396B2 (es) |
KR (1) | KR102112885B1 (es) |
CN (1) | CN104519887B (es) |
AR (1) | AR092045A1 (es) |
AU (1) | AU2013299841B8 (es) |
CA (1) | CA2879548C (es) |
CL (1) | CL2015000294A1 (es) |
CO (1) | CO7200273A2 (es) |
CY (1) | CY1122143T1 (es) |
DK (1) | DK2882440T3 (es) |
EA (1) | EA028420B1 (es) |
EC (1) | ECSP15008695A (es) |
ES (1) | ES2717911T3 (es) |
GT (1) | GT201500025A (es) |
HK (2) | HK1204976A1 (es) |
HR (1) | HRP20190537T1 (es) |
HU (1) | HUE042877T2 (es) |
IL (1) | IL236934B (es) |
IN (1) | IN2015DN00450A (es) |
JO (1) | JOP20130236B1 (es) |
LT (1) | LT2882440T (es) |
MA (1) | MA37829A1 (es) |
MX (1) | MX359403B (es) |
MY (1) | MY176031A (es) |
NZ (1) | NZ703940A (es) |
PE (2) | PE20150673A1 (es) |
PH (1) | PH12015500246A1 (es) |
PL (1) | PL2882440T3 (es) |
PT (1) | PT2882440T (es) |
RS (1) | RS58734B1 (es) |
SG (1) | SG11201500321YA (es) |
SI (1) | SI2882440T1 (es) |
TN (1) | TN2015000027A1 (es) |
TR (1) | TR201904980T4 (es) |
TW (1) | TWI607754B (es) |
UA (1) | UA115786C2 (es) |
WO (1) | WO2014025688A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102112885B1 (ko) * | 2012-08-07 | 2020-05-19 | 노파르티스 아게 | B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물 |
NZ712184A (en) | 2013-03-21 | 2020-01-31 | Array Biopharma Inc | Combination therapy comprising a b-raf inhibitor and a second inhibitor |
WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
PL3155126T3 (pl) * | 2014-06-16 | 2019-01-31 | Worldwide Innovative Network | Sposób wybierania spersonalizowanej terapii potrójnej do leczenia nowotworu |
WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
JP2018526375A (ja) * | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | 組み合わせ療法 |
WO2017037573A1 (en) * | 2015-08-28 | 2017-03-09 | Novartis Ag | Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer |
WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
UA125436C2 (uk) * | 2016-06-03 | 2022-03-09 | Еррей Біофарма, Інк. | Фармацевтичні комбінації |
CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
CA3069564A1 (en) * | 2017-08-03 | 2019-02-07 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
EP4364798A2 (en) | 2018-10-05 | 2024-05-08 | Annapurna Bio Inc. | Compounds and compositions for treating conditions associated with apj receptor activity |
TW202043225A (zh) * | 2019-01-25 | 2020-12-01 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2023145530A1 (ja) * | 2022-01-27 | 2023-08-03 | 国立大学法人東北大学 | 癌治療剤 |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
WO2024073364A1 (en) * | 2022-09-26 | 2024-04-04 | Beigene, Ltd. | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
DK2139484T3 (da) | 2007-04-10 | 2013-10-21 | Exelixis Inc | Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa |
UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
SG10201402917XA (en) * | 2009-08-24 | 2014-08-28 | Genentech Inc | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
BR112012008519A2 (pt) * | 2009-10-12 | 2016-04-05 | Glaxosmithkline Llc | combinação |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
JP2013542228A (ja) * | 2010-11-08 | 2013-11-21 | ノバルティス アーゲー | Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における2−カルボキサミドシクロアミノウレア誘導体の使用 |
CN104185631A (zh) | 2011-11-10 | 2014-12-03 | 纪念斯隆-凯特琳癌症中心 | 用2-氨基-4H-萘并[1,2-b]吡喃-3-甲腈治疗卵巢癌 |
CN103917236A (zh) * | 2011-11-11 | 2014-07-09 | 诺华股份有限公司 | 治疗增生性疾病的方法 |
KR102112885B1 (ko) * | 2012-08-07 | 2020-05-19 | 노파르티스 아게 | B-raf 억제제, egfr 억제제 및 임의로 pi3k-알파 억제제를 포함하는 제약 조합물 |
-
2013
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active IP Right Grant
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en active Application Filing
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 PH PH12015500246A patent/PH12015500246A1/en unknown
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
- 2015-06-18 HK HK15105815.5A patent/HK1204976A1/xx unknown
- 2015-11-03 HK HK15110834.2A patent/HK1211831A1/xx unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-03-19 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
NI201400083A (es) | Compuesto de imidazopirrolidinona | |
AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
CR20120419A (es) | Formulación de anticuerpos y regimenes terapéuticos | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
CR20140086A (es) | Tratamientos de combinación para hepatitis c | |
GT201000182A (es) | Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada | |
GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
ECSP14013275A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
PH12016502353A1 (en) | Pharmaceutical composition | |
CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
TW201613577A (en) | Pharmaceutical combinations | |
CO6561789A2 (es) | Método de tratamiento | |
MX2015002005A (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. | |
ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
UY33529A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias? | |
MX362905B (es) | Tratamiento de combinacion. | |
BR112015012497A2 (pt) | combinações farmacêuticas |